

Review Form 1.7

Journal Name:	Asian Journal of Research in Biochemistry
Manuscript Number:	Ms_AJRB_96437
Title of the Manuscript:	EVALUATION OF CHRONIC ADMINISTRATION OF THE CONCOMITANT COMBINATION OF ARTEMETHER- LUMEFANTRINE AND CIPROFLOXACIN ON REPRODUCTIVE HORMONES AND PROSTATE SPECIFIC ANTIGEN OF ADULT MALE WISTAR RATS
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://journalajrb.com/index.php/AJRB/editorial-policy>)

Review Form 1.7

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p><u>Compulsory</u> REVISION comments</p> <ol style="list-style-type: none"> 1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript) 2. Is the title of the article suitable? (If not please suggest an alternative title) 3. Is the abstract of the article comprehensive? 4. Are subsections and structure of the manuscript appropriate? 5. Do you think the manuscript is scientifically correct? 6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form. <p><u>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</u></p>		
<p><u>Minor</u> REVISION comments</p> <ol style="list-style-type: none"> 1. Is language/English quality of the article suitable for scholarly communications? 	<p>Review of the article EVALUATION OF CHRONIC ADMINISTRATION OF THE CONCOMITANT COMBINATION OF ARTEMETHER- LUMEFANTRINE AND CIPROFLOXACIN ON REPRODUCTIVE HORMONES AND PROSTATE SPECIFIC ANTIGEN OF ADULT MALE WISTAR RATS</p> <p>The findings of this study that the co-administration of artemether/lumefantrine and ciprofloxacin may adversely affect reproductive functions and lead to infertility but may not lead to prostate cancer in males are a significant contribution. It is within the scope of the journal and suitable for publication after some revision.</p> <p>On page 1, in the abstract, paragraph 1, .line 1, the first small letter can be used for lumefantrine Line 2, second-generation can be connected Line 5, use comma before, such Line 8, use one space between the adequate number and the unite of measure, for example, 20 mg/120 mg/kg body weight, as well as in the rest of the manuscript, Line 9, use onse space and delete one space adequately, as follows, within 125 mg/kg body weight Use commas before and after, respectively, Line 13, state in plural data were analyzed Lines 15 and 17, either the abbreviation or full term can be sttaed for the mentioned hormones, since this has been explained at the first place where it appears in the text of the manuscript, in lines 5 and 6</p>	

Review Form 1.7

	<p>The abbreviations should be stated after the full terms at the first place where they appear in the manuscript Line 17, use small letter for $p < 0.05$, like in line 14, as well as in the rest of the manuscript Line 18, comma can be used before, when Line 21, use comma before, but</p> <p>In keywords, use a slash within Artemether/lumefantrine</p> <p>Paragraph 2, line 3, delete repeated word Africa Line 5, delete one space within an infectious disease Line 7, delete one space after mortality</p> <p>Paragraph 3, line 2, use comma before, due to and before, such as</p> <p>On page 2, paragraph 1, line 1, either the abbreviation or full term can be stated for artemisinin-based combination therapy Line 3, use comma before, such as</p> <p>Paragraph 2, line 1, use comma before, which and subscripts in the formula ($C_{16}H_{26}O_5$) Line 2, use subscripts in the formula and place comma after brackets ($C_{30}H_{32}C_{13}NO$), Line 5, the first small letters can be used for chemicals or drugs, such as artemether–lumefantrine, as well as within the entire manuscript, except at the beginning of the sentence, where the first capital letter should be used</p> <p>Paragraph 3, line 3, add a space before year within (Jawad et al., 2020), use comma before, such as Line 5, state correct derivatives, artemether/lumefantrine Paragraph 5, line 3, comma can be used before, which Paragraph 6, line 6, use one space within 2 % Paragraph 7, line 1, state after comma, which is produced or start a new sentence after dot with It is produced</p> <p>On page 3, paragraph 1, line 2, use a space before and within (Aprioku, and Obianime, 2011) State correct numbers for subheadings 2.2 Experimental Animals 2.3 Experimental Protocol Paragraph 4, line 4, use spaces adequately within 100 g – 120 g Line 3, delete one space before They Paragraph 6, line 2, use comma instead of and before, blood samples were obtained, delete one space before immediately Line 3, correct spelling at the beginning of the sentence is The serums Line 5, use a space within 10 % Line 6, comma can be used before, prior to</p> <p>On page 4, state correct numbers of subheadings 2.6 Histological Analysis, and delete two enters before this subheading 2.7 Data Analysis Paragraph 3, line 5, use singular for photomicrograph</p>	
--	--	--

Review Form 1.7

	<p>Line 6, charge-coupled should be connected State the adequate numbers of subheadings within section 3. Results Subsequently, subheadings 3.1.1 and 3.1.2, as well as legends of Figures 1 and 2 and caption of Table 1 can be supplemented, when listing, as follows treated with artemether/lumefantrine, ciprofloxacin and their concomitant combination Paragraph 5 on this page, line 3, put comma before and after, however, Lines 4 and 5, state significantly decreased relative reproductive organ weight (p value <0.05) Place Figure 1 below this paragraph Paragraph 6, line 1, begin the sentence with From Table 1 Line 4, comma can be placed before, when and while Line 6, state at this end of the sentence (Table 1) Place Table 1 below this paragraph</p> <p>Move to the next row, below Table 1 the next sentence beginning with However and end this sentence with (Figure 2). Place Figure 2 below this sentence</p> <p>On page 5, in Figure 1, the square next to Control should be green. Resolution or color of letters in Figures 1 and 2 can be improved. On page 6, paragraph 1, line 1, delete one space after showed Line 6, use plural for Plates 1, 2, 3 and 4</p> <p>In the legends of Plates 1, 2, 3 and 4, begin the first sentence with the first capital letter Photomicrograph In the legends of Plates 2, 3 and 4, delete one slash within 20/120 mg/kg bw, 125 mg/kg bw and 20/120 mg/kg bw</p> <p>On page 8, in discussion, paragraph 1, line 3, put comma before, which</p> <p>On page 9, paragraph 1, line 5, put comma before, which Paragraph 2, line 15, correct spelling is ciprofloxacin Paragraph 5, line 3, comma can be used before, when</p> <p>On page 10, paragraph 1, line 1, comma can be used before, where Paragraph 2, lines 5, 10 and 11, place comma before, which and while Paragraph 3, line 4, put dot at the end of the sentence, after apoptosis. Line 9, put comma before, which Paragraph 4, line 3, use comma before, which Paragraph 5, line 2, three spaces should be deleted after cells. Line 4, place comma before, which Paragraph 6, line 2, delete repeated word ciprofloxacin</p> <p>Add issue numbers to references 1, 4, 5 and 26 Add the last page numbers to references 5, 11, 12, 16 State article ID or the last page in reference 18</p> <p>Format the entire manuscript uniformly, according to the style of the journal. The English language should be improved at some places.</p>	
--	--	--

Review Form 1.7

Optional/General comments	The findings of this study that the co-administration of artemether/lumefantrine and ciprofloxacin may adversely affect reproductive functions and lead to infertility but may not lead to prostate cancer in males are a significant contribution. It is within the scope of the journal and suitable for publication after some revision.	
----------------------------------	---	--

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i> There are no ethical issues in this manuscript.	
Are there competing interest issues in this manuscript?	There are no competing interests in this manuscript.	
If plagiarism is suspected, please provide related proofs or web links.	There is no plagiarism suspected in this manuscript.	

PART 3: Declaration of Competing Interest of the reviewer:

<p>Here reviewer should declare his/her competing interest. If nothing to declare he/she can write "I declare that I have no competing interest as a reviewer"</p> <p>I declare that I have no competing interest as a reviewer.</p>
--

PART 4: Objective Evaluation:

Guideline	MARKS of this manuscript
<p>Give OVERALL MARKS you want to give to this manuscript (Highest: 10 Lowest: 0)</p> <p>Guideline: Accept As It Is: (>9-10) Minor Revision: (>8-9) Major Revision: (>7-8) Serious Major revision: (>5-7) Rejected (with repairable deficiencies and may be reconsidered): (>3-5) Strongly rejected (with irreparable deficiencies.): (>0-3)</p>	<p>Minor Revision: (>8-9)</p>

Review Form 1.7

PART 5: Reviewer Details:

This information is mandatory to prepare the Reviewer Certificate properly.

Certificate preparation will not be possible if incomplete information is received.

Name of the Reviewer	Tamara Jovanovic
Department of Reviewer	Biomedical Engineering
University or Institution of Reviewer	Faculty of Mechanical Engineering, University of Belgrade
Country of Reviewer	Serbia
Position: (Professor/lecturer, etc.) of Reviewer	Dr, PhD, Associate Research Professor
Email ID of Reviewer	tamara.jovanovic@sbb.rs tjovanovic@mas.bg.ac.rs
WhatsApp Number of Reviewer	+381 11 3541 885
5-8 Keywords regarding expertise of Reviewer	Materials, chemistry, medicinal and pharmaceutical chemistry, chemical technologies, nanotechnologies, biomedical engineering, spectroscopy